Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Gen Psychiatry ; 63(4): 450-6, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16585475

ABSTRACT

CONTEXT: Although the behavioral effects of high-dose androgen administration may involve alterations in serotonergic activity, few studies have investigated the impact of androgen withdrawal on the central nervous system in humans. OBJECTIVE: To examine the effects of pharmacologically induced hypogonadism on several cerebrospinal fluid (CSF) systems that could mediate the behavioral concomitants of hypogonadism. DESIGN: Double-blind assessment of the effects of the short-term induction of hypogonadism and subsequent replacement with testosterone and placebo in a crossover design. SETTING: National Institutes of Health, Bethesda, Md. PARTICIPANTS: Twelve healthy male volunteers. INTERVENTIONS: We administered the gonadotropin-releasing hormone agonist leuprolide acetate (7.5 mg intramuscularly every 4 weeks) to the healthy male volunteers, creating a hypogonadal state, and then either replaced testosterone (200 mg intramuscularly) or administered a placebo every 2 weeks for 1 month. MAIN OUTCOME MEASURES: Mood and behavioral symptoms were monitored with daily self-ratings, and lumbar punctures were performed during both hypogonadal (placebo) and testosterone-replaced conditions for CSF levels of steroids and monoamine metabolites. RESULTS: The CSF testosterone, dihydrotestosterone, and androsterone levels were significantly lower during hypogonadism (P=.002, .04, and .046, respectively), but no significant changes were observed in CSF measures of 5-hydroxyindoleacetic acid, homovanillic acid, dehydroepiandrosterone, or pregnenolone. Decreased sexual interest was observed during the hypogonadal state compared with both baseline and testosterone replacement (P=.009) and correlated significantly with CSF measures of androsterone during both hypogonadism and testosterone replacement (r = -0.76 and -0.81, respectively; P<.01). Moreover, the change in severity of decreased sexual interest correlated significantly with the change in CSF androsterone levels between testosterone replacement and hypogonadism (r = -0.68; P<.05). The CSF 5-hydroxyindoleacetic acid and homovanillic acid levels did not correlate significantly with any behavioral or CSF measure. CONCLUSION: These data suggest that the neurosteroid androsterone contributes to the regulation of sexual function in men.


Subject(s)
Androsterone/physiology , Hypogonadism/chemically induced , Leuprolide/pharmacology , Sexual Behavior/physiology , Adolescent , Adult , Affect/drug effects , Affect/physiology , Androsterone/blood , Androsterone/cerebrospinal fluid , Androsterone/metabolism , Cross-Over Studies , Dihydrotestosterone/blood , Dihydrotestosterone/cerebrospinal fluid , Double-Blind Method , Estradiol/blood , Humans , Hypogonadism/blood , Hypogonadism/cerebrospinal fluid , Injections, Intramuscular , Leuprolide/administration & dosage , Male , Middle Aged , Radioimmunoassay , Sexual Behavior/drug effects , Spinal Puncture , Testosterone/blood , Testosterone/cerebrospinal fluid , Testosterone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL